 Aptorum Group Limited NASDAQ: APM Aptorum Group, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing of a registered direct offering of 1,351,350 Class A ordinary shares and warrants to purchase 1,351,350 of its Class A ordinary shares at an exercise price of 7.40 per share. The combined purchase price for one Class A ordinary share and one warrant will be 7.40. The gross proceeds to Aptorum Group from the registered direct offering are expected to be approximately 10 million, before deducting the placement agents fees and other estimated offering expenses. Participation in the offering includes approximately 6 million from unaffiliated institutional investors and 4 million from Jurchen Investment Corporation, the largest shareholder of Aptorum Group, which is wholly owned by Ian Huen, the Chief Executive Officer and Executive Director of Aptorum Group. The offering is expected to close on February 28, 2020, subject to customary closing conditions. 